Small molecule · developed by Keros Therapeutics
KER-047 is an oral tablet studied for the treatment of iron deficiency anemia, taken daily or every other day.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05927012 | Phase 2 | Iron Deficiency Anemia | Withdrawn | KROS |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Iron Deficiency Anemia
Updated Oct 18, 2026. Something wrong or missing? Report it on the KROS page.
See KROS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KROS catalysts and pipeline →